Last reviewed · How we verify
BMS-986195
At a glance
| Generic name | BMS-986195 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis (PHASE2)
- A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants (PHASE1)
- The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients (PHASE1)
- Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects (PHASE1)
- A Study of BMS-986195 in Healthy Male Subjects (PHASE1)
- Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986195 CI brief — competitive landscape report
- BMS-986195 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI